NCT00136396View on ClinicalTrials.gov

Rituximab Therapy for Steroid-Refractory Chronic Graft Versus Host Disease

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

January 31, 2004

Primary Completion Date

November 30, 2006

Study Completion Date

November 30, 2010

Conditions
Graft vs Host Disease
Interventions
DRUG

Rituximab

Given once weekly for 4 weeks followed by a 4 week observation therapy.

Trial Locations (2)

02115

Brigham and Women's Hospital, Boston

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
collaborator

Brigham and Women's Hospital

OTHER

lead

Dana-Farber Cancer Institute

OTHER

NCT00136396 - Rituximab Therapy for Steroid-Refractory Chronic Graft Versus Host Disease | Biotech Hunter | Biotech Hunter